logo

Axovant Sciences Ltd. (AXON)



Trade AXON now with
  Date
  Headline
3/11/2019 6:38:19 AM Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy
12/14/2018 9:05:06 AM Axovant Sciences Prices Public Offering Of 30 Mln Shares At $1.00/shr
12/10/2018 7:04:14 AM Axovant Reports Results Of Exploratory Phase 2 Study Of Nelotanserin In Lewy Body Dementia Patients
12/6/2018 7:14:23 AM Axovant Reports Feedback From FDA Meeting Regarding AXO-Lenti-PD For Parkinson’s Disease
11/26/2018 8:06:49 AM Axovant Sciences Adds Five Senior Team Members To Support Gene Therapy Pipeline
10/25/2018 2:47:22 AM Axovant Sciences Doses First Patient In Clinical Study Of AXO-Lenti-PD
7/8/2018 8:45:41 PM Axovant Announces Licensing Agreement For AXO-AAV-OPMD Program For Treatment Of Oculopharyngeal Muscular Dystrophy
6/6/2018 2:15:05 AM Oxford BioMedica Enters Exclusive Worldwide Licensing Agreement With Axovant
6/6/2018 2:05:50 AM Axovant Sciences Licenses Exclusive Worldwide Rights To Develop OXB-102, Now AXO-Lenti-PD, From Oxford BioMedica
2/12/2018 7:02:11 AM Axovant Sciences CEO David Hung Resigns To Pursue Other Opportunities